CureDM
A bio Pharma Success Story
Monday, June 13, 2011
Embassy Suites, Chesterbrook, Pennsylvania (directions)
|
About
|
A bit over a year ago, CureDM signed an agreement with Sanofi-Aventis, in a deal amounting $335 million, for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type1 and type2 diabetes.
CureDM has presentedto PCCI twice before and now returns in PCCI's "Where are they now" series to tell us all about their success.
CureDM is a BioPharmaceutical Company focused on the discovery and development of new therapies that prevent, ameliorate, or reverse diseases of metabolism.
Pancreate™ is a bioactive peptide sequence of a naturally occurring human protein that stimulates the formation of functional insulin producing islets from pancreatic progenitor cells. In both type1 and type2 diabetes, a fundamental problem is too few insulin-producing islets to keep up with insulin demand. In addition, islets provide the necessary metabolic control of insulin release that makes the pancreas so uniquely able to keep a consistent glucose level in the blood. Restoring whole islets is paramount to correcting the erratic blood glucose fluctuations associated with diabetes, making Pancreate™a fundamentally new approach to the treatment of diabetes.
Program:
|
6:00 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)
8:00 - Presentation and Discussion
<Top of the page>
|
 |
 Slides
None available at this time
 Audio
None available at this time
 Video
None available at this time
 Webcast
CureDM Webcast 06/11
|
|
|
